

## Daliresp® (roflumilast) – First-time generic

- On October 20, 2020, Micro Labs, Viatris, <u>Zydus</u>, Solco, Novadoz/MSN, and <u>Camber launched</u> AB-rated generic versions of AstraZeneca's <u>Daliresp</u> (roflumilast) 500 mcg tablets.
  - In addition, Novadoz launched MSN's <u>AB-rated</u> generic version of Daliresp 250 mcg tablets.
- Daliresp is approved as a treatment to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.